Regenesis Biomedical raises $5.3 million in series C funding

About This Report

Abstract:

Regenesis Biomedical, Inc., a medical technology company focused on developing and marketing noninvasive regenerative medicine products, has completed $5.3 million in series C equity financing led by Fulcrum Equity Partners and TGap Ventures, and includes existing investor Solstice Capital.

Following terms and conditions apply: All charges are made in USD. Actual charge to your credit card may deviate due to the currency exchange and Bank fees from your financial institution as some banks and credit cards impose fees for international transactions outside the United States. If you have any questions about these fees or the exchange rate applied to your booking, please contact your bank.